Hualan Biological Engineering Inc. (SHE:002007)
14.54
+0.12 (0.83%)
May 8, 2026, 3:04 PM CST
SHE:002007 Revenue
Hualan Biological Engineering had revenue of 762.11M CNY in the quarter ending March 31, 2026, a decrease of -12.16%. This brings the company's revenue in the last twelve months to 4.49B, up 0.67% year-over-year. In the year 2025, Hualan Biological Engineering had annual revenue of 4.60B with 4.93% growth.
Revenue (ttm)
4.49B
Revenue Growth
+0.67%
P/S Ratio
5.92
Revenue / Employee
1.09M
Employees
4,117
Market Cap
26.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.60B | 215.82M | 4.93% |
| Dec 31, 2024 | 4.38B | -962.68M | -18.02% |
| Dec 31, 2023 | 5.34B | 824.89M | 18.26% |
| Jan 1, 2023 | 4.52B | 80.78M | 1.82% |
| Jan 1, 2022 | 4.44B | -587.01M | -11.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chongqing Zhifei Biological Products | 8.75B |
| Shanghai RAAS Blood Products | 6.85B |
| Beijing Tiantan Biological Products | 5.99B |
| Shanghai Allist Pharmaceuticals | 5.67B |
| Yili Chuanning Biotechnology | 4.41B |
| Xiamen Amoytop Biotech | 3.82B |
| Suzhou Zelgen Biopharmaceuticals | 1.55B |
| Jinyu Bio-technology | 1.39B |